NGM Biopharmaceuticals Inc (OQ:NGM)

Dec 05, 2019 05:00 pm ET
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who...
Nov 14, 2019 08:00 am ET
NGM Bio to Present at the Stifel 2019 Healthcare Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel...
Nov 12, 2019 04:05 pm ET
NGM Reports Business Highlights and Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM or the Company) (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today reported...
Oct 29, 2019 07:00 am ET
NGM Bio Announces Appointment of Valerie Pierce as General Counsel
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Valerie Pierce as Senior Vice President, General Counsel and Chief...
Oct 18, 2019 07:00 pm ET
NGM Bio to Present at Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present at two upcoming conferences focused on drug research and...
Oct 07, 2019 08:00 am ET
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced positive...
Oct 06, 2019 04:00 pm ET
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss preliminary results from a planned, pre-specified interim analysis of the aldafermin 1 mg...
Oct 03, 2019 07:00 am ET
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced multiple aldafermin (NGM282) poster presentations at...
Aug 12, 2019 04:05 pm ET
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
--Completed enrollment of 1 mg cohort of 24-week Phase 2 study of NGM282 (aldafermin) in NASH patients; Planned data readouts over next 3 – 6 months-- --Robust clinical stage pipeline now spans novel drugs to address significant unmet needs in...
Jun 10, 2019 07:00 am ET
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Aetna Wun Trombley,...
Jun 05, 2019 07:00 am ET
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present new data from a Phase 1b study of NGM313 at the 79th Scientific...
May 16, 2019 04:05 pm ET
NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today provided a business update and reported first quarter 2019 financial results for the period...
Apr 08, 2019 04:30 pm ET
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced multiple presentations at European Association for the...
Apr 03, 2019 08:58 pm ET
NGM Bio Announces Pricing of Initial Public Offering
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to...